How much is the metered dose inhaler devices market worth, and how is it expected to expand?
The metered dose inhaler devices market size has grown strongly in recent years. It will grow from $15.46 billion in 2024 to $16.36 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, increased demand for metered dose inhaler devices, increased metered dose inhaler devices, increased demand for metered dose inhaler devices, and increased prevalence of COPD.
The metered dose inhaler devices market size is expected to see strong growth in the next few years. It will grow to $20.29 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to the increasing prevalence of chronic obstructive pulmonary diseases, rising prevalence in asthma, increasing prevalence of infectious diseases, rising prevalence of diabetes, and increasing incidence of respiratory diseases. Major trends in the forecast period include technological advancements, innovative therapies, regulatory approvals, innovations of new inhalers, and adoption of online marketing tools.
Get Your Free Sample of The Global Metered Dose Inhaler Devices Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20878&type=smp
Which industry factors have accelerated the metered dose inhaler devices market’s expansion?
The increasing prevalence of chronic obstructive pulmonary diseases is expected to propel the growth of the metered dose inhaler devices market going forward. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by airflow obstruction, typically caused by long-term exposure to irritants such as cigarette smoke, leading to symptoms such as shortness of breath, coughing, and wheezing. The increasing prevalence of chronic obstructive pulmonary disease (COPD) is driven by factors such as tobacco use, air pollution, aging populations, and delayed diagnosis or treatment. Metered dose inhaler (MDI) devices help manage chronic obstructive pulmonary disease (COPD) by delivering medication directly to the lungs, providing fast relief and improving airflow. For instance, in December 2023, according to the National Institutes of Health, a US-based government agency, the number of COPD cases is projected to rise from 532 million in 2030 to a total of 592 million by 2050. Therefore, the increasing prevalence of chronic obstructive pulmonary diseases is driving the growth of the metered dose inhaler devices market.
What are the primary segments of the metered dose inhaler devices market?
The metered dose inhaler devices market covered in this report is segmented –
1) By Type: Desktop Metered Dose Inhaler Devices, Portable Metered Dose Inhaler Devices, Other Types
2) By Distribution Channel: Online, Offline
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Other Applications
4) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Desktop Metered Dose Inhaler Devices: Standard desktop MDI devices, High-performance desktop MDI devices, Smart desktop MDI devices
2) By Portable Metered Dose Inhaler Devices: Conventional portable MDI devices, Advanced portable MDI devices, Smart portable MDI devices
3) By Other Types: Nebulizer-Based MDI devices, Dry powder inhaler (DPI) combined devices, Soft mist inhaler (SMI) devices, Other specialized MDI devices
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/metered-dose-inhaler-devices-global-market-report
Which firms are leading the metered dose inhaler devices market?
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB
Which market trends are set to define the future of the metered dose inhaler devices market?
Major companies operating in the metered dose inhaler devices market are focused on developing technologically advanced solutions, such as pressurized metered dose inhalers, to enhance drug delivery efficiency and improve patient compliance. Pressurized metered-dose inhalers (pMDIs) are inhalation devices that deliver a precise amount of medication in aerosol form using a pressurized propellant. For instance, in July 2023, Lupin Limited, an India-based pharmaceutical company, launched Luforbec 100/6, a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This product combines beclometasone (100 µg) and formoterol (6 µg), providing an effective solution for patients requiring combination therapy. Notably, Luforbec is priced approximately 47% lower than the fixed reference price, enhancing its accessibility. With asthma affecting about 5% of adults in Germany, this launch underscores Lupin’s commitment to addressing critical healthcare needs and improving patient outcomes in respiratory care.
Which geographic trends are shaping the metered dose inhaler devices market, and which region has the highest market share?
North America was the largest region in the metered dose inhaler devices market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Metered Dose Inhaler Devices Market Report 2025 Offer?
The metered dose inhaler devices market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Metered dose inhaler (MDI) devices refer to medical devices designed for delivering precise doses of aerosolized medication directly to the lungs through inhalation. These devices are commonly used in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other breathing disorders.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20878
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
